Browsing Tag
Aflibercept
6 posts
Why Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) just strengthened the Eylea HD case against Roche’s Vabysmo
Regeneron won FDA approval for every-20-week Eylea HD dosing in wet AMD and DME. Read what it means for Regeneron, rivals, and retinal drug markets.
April 4, 2026
Can Celltrion’s Eydenzelt disrupt Canada’s aflibercept market after Health Canada approval?
Celltrion secures Health Canada approval for Eydenzelt, its aflibercept biosimilar. Explore how it aims to disrupt Canada’s high-cost eye care drug market.
November 30, 2025
Kodiak Sciences’ KSI-301 fails to meet primary endpoint in wet AMD trial
Kodiak Sciences said that its antibody biopolymer conjugate KSI-301 failed to meet the primary endpoint in a phase…
February 27, 2022
DAZZLE clinical trial : Kodiak Sciences doses first patients with KSI-301 in phase 3 wet AMD trial
Kodiak Sciences said that it has treated the first patients in the phase 2 DAZZLE clinical trial of…
October 15, 2019
Novartis bags Beovu FDA approval for wet AMD
Beovu FDA approval for wet AMD : Swiss pharma giant Novartis has been given approval from the US…
October 9, 2019
FDA approves updated label for Regeneron’s EYLEA treating wet AMD
In a significant development for ophthalmic care, Regeneron Pharmaceuticals has received approval from the U.S. Food and Drug…
August 19, 2018